US Pharmacopeial Convention Announces Revised Official Dates for Elemental Impurities Chapters - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

US Pharmacopeial Convention Announces Revised Official Dates for Elemental Impurities Chapters


ePT--the Electronic Newsletter of Pharmaceutical Technology

The United States Pharmacopeial Convention (USP) published General Chapters <232> Elemental Impurities—Limits and <233> Elemental Impurities—Methods in USP 35-NF 30, Second Supplement, with a Dec. 1, 2012 official date, but this official date was postponed to consider an appeal of the two general chapters. In January 2013, the USP Executive Committee of the Council of Experts (CoE EC) ruled to uphold the two general chapters and re-established their official date as Feb. 1, 2013, according to a Jan. 28, 2013 Revision Bulletin. There are no requirements for articles covered by an applicable USP–NF monograph to comply with the general chapters’ provisions on this official date, but companies can now use the general chapters to prepare for the proposed implementation date in 2014.

In considering the appeal, the Executive Committee found that USP followed its processes and adequately considered appellants’ comments, and that there were no new data or evidence presented to justify further consideration or continued postponement. The provision to make General Chapters <232> and <233> applicable to all articles in the compendia (except where noted otherwise) on May 1, 2014 has been proposed in the Jan–Feb 2013 Pharmacopoeial Forum (PF) 39(1) and is open for public comment until Mar. 31, 2013. USP may also consider further revisions based on new information, such as information from ongoing International Conference on Harmonization (ICH) deliberations.

Typically, a standard becomes official six months after publication in a book or supplement, and implementation is required as of that official date. In this case, however, the official date is separate from the implementation date, noted USP in the Revision Bulletin. Implementation will not occur until the general chapters are referenced in a monograph or in General Notices, which is proposed to occur on May 1, 2014. The Executive Committee encourages those with specific issues regarding applying the new general chapters to a particular monograph or monographs to work with USP and the relevant Expert Committees to gain resolution prior to the planned implementation of the general chapters next year.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
20%
To all process for new products only
13%
To select process for new products only
24%
To select processes for both new and legacy products
20%
Do not use QbD
22%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Inadequate Access to Medicines Puts EU at Risk
FDA Offers Insight on QbD for Modified-Release Products
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
FindPharma Custom Search
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here